Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
2(100.0%)
2Total
N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06011512Completed

Risk of Diabetes Mellitus in Patients With Giant Cell Arthritis and Polymyalgia Rheumatica.

Role: lead

NCT04335747Terminated

COVID-19 Infection in Vulnerable Patients With Inflammatory Rheumatic Diseases

Role: lead

NCT04411407Not ApplicableCompleted

PROM Collected Via a WebApp Versus a Touch Screen Solution Among Patients With SLE

Role: lead

NCT03486613Not ApplicableCompleted

PROM Collected Via a Smartphone App Versus a Touch Screen Solution Among Patients With Inflammatory Arthritis

Role: lead

All 4 trials loaded